Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma

25 Jun 2025

Abstract excerpt

Research during the past decades has revealed a complex, aberrant DNA methylation profile in multiple myeloma (MM), playing a key role in disease progression, prognosis, and therapy response.However, spatial epigenetic heterogeneity may cause underestimation of alterations in the DNA methylation profile when analyzing single bone marrow (BM) aspirates.Liquid biopsies, particularly cell-free DNA (cfDNA), have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Multiple Myeloma Research and Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40561508
DOI: 10.1182/bloodadvances.2025016480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myelomaPMID 40561508Read ↗

DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell TumorsSemantic proximity Read ↗

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSemantic proximity Read ↗

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosisSemantic proximity Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor DiseasesSemantic proximity Read ↗

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Semantic proximity Read ↗

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Semantic proximity Read ↗

Diagnosis and Prediction of Precursor States in Multiple Myeloma using Cell-free ChromatinSemantic proximity Read ↗

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaSemantic proximity Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.Semantic proximity Read ↗

The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.